Savvy Trades and Investments

[researcher59]

JAZZ +6 to 145 after posting strong Q4 earnings -

briefing -

Jazz Pharma beats by $0.79, beats on revs; guides FY25 EPS above consensus, revs in-line (139.67 +2.98) :
Reports Q4 (Dec) earnings of $6.60 per share, excluding non-recurring items, $0.79 better than the FactSet Consensus of $5.81; revenues rose 7.5% year/year to $1.09 bln vs the $1.06 bln FactSet Consensus.
Co issues guidance for FY25, sees EPS of $22.50 to $24.00, excluding non-recurring items, vs. $22.03 FactSet Consensus; sees FY25 revs of $4.150 bln to $4.400 bln vs. $4.32 bln FactSet Consensus.